Skip to main content
OpenTrials
Completed

NCT Number: NCT02570217

HHHFNC (Heated Humidified High-Flow Nasal Cannula) Versus NCPAP for Respiratory Distress Syndrome of Prematurity

Preterm infants ranging from 29+0 to 36+6 weeks+days are randomly assigned to one of the following treatments as non invasive respiratory support if they develop mild to moderate Respiratory Distress Syndrome within 72 hrs from birth: 1) NCPAP set at 4-6 cmH2O or 2) HHHFNC providing a flow 4-6 l/min.

The aim of the study is to assess efficacy and safety of relative "new" form of respiratory support (HHHFNC) versus a more common one (NCPAP).

Completed

Looking for future studies?

Notify Me

Key information

Age range

29 week–36 week

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

NICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy

Milan, 20122, Italy

About this study

Preterm infants are eligible to the study if they present mild to moderate Respiratory Distress Syndrome (RDS) defined by the following criteria: need of FiO2 ( Fraction of Inspired Oxygen) ≥0.30 to keep a target SpO2 (Periferal Oxygen Saturation) beetween 88-93% and/or Silverman score ≥5. To confirm the diagnosis a Chest XR is performed as routinarily in the ward before starting the respiratory support.

They are randomly assigned to one of the treatment groups cited in "brief summary" by means of closed envelops. A block randomization is applided with a blok size of 4. The randomization is stratified per groups accoring to gestational age: from 29+0 to 32+6; from 33+0 to 34+6; from 35+0 to 36+6 weeks+days.

Once the treatment is started, for the group NCPAP there is the possibility to switch to the mode "Bi-PAP" if: there are more than 4 episodes of apnoea per hour or more than 2 episodes requiring positive pressure ventilation or if deemed by clinicians for increased work of breathing assesed by the Silverman score.

For all the groups, if the FiO2 requirement is persistently higher than 0.35-0.40 per target SpO2 86-93% and/or dyspnoea defined by Silverman score > 6 after starting the respiratory support, newborns receive Surfactant by "INSURE" technique, involving endotracheal intubation by direct laryngoscopic vision, endotracheal administration of surfactant (Curosurf, Chiesi Pharmaceutics, Parma, Italy) 200 mg/kg and finally extubation.

After the administration of surfactant, if FiO2 requirement is persistently >0.4 to keep SpO2 86-93% or severe apnea episodes are present (apnea episodes > 4/hr or >2/hr requiring positive pressure ventilation) or at the blood gas (capillary or venous) PaCO2>70 mmHg and pH<7.20, newborns are intubated and mechanically ventilated.

For all the newborns enrolled in the study, capillary or venous blood gas is checked every 6-12 hours, a cerebral and cardiac ultrasound screening is performed within 24 hrs. Further controls follow the routine of the ward.

Weaning is started decreasing HHHFNC flow by 1 lpm or nCPAP pressure by 1 cmH2O pressure if infants are presenting FIO2 < 0.30 to target SpO2 and minimal or no signs of respiratory effort. The respiratory support is discontinued for flow ≤ 2 lpm or pressure ≤ 2 cmH2O.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Inborn
  • Parental Consent

Exclusion criteria

  • No parental consent
  • Major congenital malformations
  • Severe intra ventricular hemorrage diagnosed early after birth

Treatment and study plan

HHHFNC

Device

infants receive non-invasive respiratory support by mean of HHHFNC

Other names: PRECISION FLOW (Vapotherm,Stevensville, USA)

NCPAP

Device

infants receive non-invasive respiratory support by mean of NCPAP

Other names: Infant Flow Driver System (EME Ltd, Brighton, Sussex, UK), SiPAP (Viasys Healthcare, Palm Springs, CA)

Primary outcomes

  1. number of patients needing intubation and mechanical ventilation within 72 hrs from the beginning of the study mode

    Time frame: within 72 hrs from the beginning of the study mode

    The procedure defined as INSURE and described in details in the section "Detailed Study Description" is not considered as a failure for the primary outcome.

Secondary outcomes

  1. overall duration of respiratory assistance

    Time frame: up to 2 years from birth

    respiratory assistance includes both invasive and non invasive respiratory supports

  2. overall duration of oxygen requirement

    Time frame: up to 2 years from birth

    Apart from invasive and non invasive respiratory supports, for this specific outcome are considered also the days of oxygen administration by devices other then ventilators or HHHFNC devices.

  3. overall duration of non invasive respiratory assistance

    Time frame: up to 2 years from birth

    If later during the hospitalisation the newborn receive non invasive ventilation, even if for different reasons from the beginning and/or by mean of a different mode or device, this is registered and computed as "overall non invasive ventilation".

  4. Surfactant treatment

    Time frame: through study completion, an average of 1 year

    the overall number of doses of surfactant are considered

  5. full enteral feeding

    Time frame: through study completion, an average of 1 year

    Number of days required to reach the " full enteral feeding" (defined by a fluids intake about 120 ml/kg/day by enteral administration)

  6. overall duration of hospitalisation

    Time frame: up to 2 years from birth

  7. air-leak syndrome

    Time frame: through study completion, an average of 1 year

  8. Intra ventricular Hemorrage

    Time frame: through study completion, an average of 1 year

  9. Patent Doctus Arterious

    Time frame: through study completion, an average of 1 year

    If a pharmaceutical or surgical treatment is required is considered. Small doctuses closing spontaneously during the first days of life are not included.

  10. Infections

    Time frame: through study completion, an average of 1 year

    Sepsis, pneumonia, cellulites and other infections are considered

  11. Necrotising Enterocolites (NEC)

    Time frame: through study completion, an average of 1 year

  12. Bronchopulmonary Dysplasia

    Time frame: up to 2 years from birth

    Jobe-Bancalari classification criteria are applied.

  13. Retinopathy of Prematurity

    Time frame: through study completion, an average of 1 year

  14. overall mortality

    Time frame: through study completion, an average of 1 year

Sponsors and collaborators

Lead sponsor

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Other

Collaborators

  • Dr Anna Lavizzari
  • Dr Francesca Gaia Ciuffini

Registry information

Official study title

HHHFNC (Heated Humidified High-Flow Nasal Cannula) Versus NCPAP (Nasal Continuous Positive Airway Pressure) in Preterm Infants With Mild to Moderate Respiratory Distress Syndrome (RDS): a Randomized Clinical Trial.

Important dates

Study start
2012
Primary completion
2014
Study completion
2014
First posted
Oct 7, 2015
Registry last updated
Oct 7, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.